Tags : Chong Kun Dang

Insights+ Key Biosimilars Events of July 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have […]Read More

Chong Kun Dang and Dong-A ST Plan to Launch Nesp

Shots: The companies filed for their Nesp biosimilar in Oct’2018 with its awaited launch in H2’19 The original drug was developed in collaboration with US’ Amgen and Japan’s Kyowa Hakko while the patent expired in the US AND Korea in 2015 and 2024. The worldwide sales for Nesp is expected to be $3B  Nesp (darbepoetin […]Read More